PRESS RELEASE published on 02/27/2025 at 08:57, 1 month 15 days ago Inside Information / News release on accounts, results GenSight Biologics reports estimated full-year 2024 consolidated financial results. Cash runway extended to early April 2025. Resumption of Compassionate Access Program expected in April 2025 Financial Results 2024 GenSight Biologics Cash Runway Compassionate Access Program
BRIEF published on 02/12/2025 at 07:35, 2 months 2 days ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
PRESS RELEASE published on 02/12/2025 at 07:30, 2 months 2 days ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
BRIEF published on 01/23/2025 at 18:50, 2 months 21 days ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 2 months 21 days ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 2 months 30 days ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 2 months 30 days ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 3 months 1 day ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
BRIEF published on 12/24/2024 at 20:51, 3 months 20 days ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 3 months 20 days ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
Published on 04/14/2025 at 14:00, 28 minutes ago Zentek Announce Strategic Partnership with Filtration Solutions Industrial Co. to Manufacture and Distribute Graphene-Enhanced HVAC Filters
Published on 04/14/2025 at 13:30, 58 minutes ago Condor Resources Announces Life Offering Private Placement of Up to $1.5 Million
Published on 04/14/2025 at 13:00, 1 hour 28 minutes ago Honey Badger Silver Appoints Williams Executive Chairman and Interim CEO
Published on 04/14/2025 at 13:00, 1 hour 28 minutes ago AmeriTrust Announces 2024 Annual Financial Results
Published on 04/14/2025 at 13:00, 1 hour 28 minutes ago Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
Published on 04/14/2025 at 13:51, 36 minutes ago Custodian Property Income REIT plc: Interim dividend
Published on 04/14/2025 at 13:09, 1 hour 18 minutes ago Original-Research: Knaus Tabbert AG (von First Berlin Equity Research GmbH): Kaufen
Published on 04/14/2025 at 11:51, 2 hours 36 minutes ago Dalata Hotel Group PLC: HOL-Holding(s) in Company*
Published on 04/14/2025 at 08:15, 6 hours 12 minutes ago Aéroports de Paris SA - Filing of the 2024 Universal Registration Document
Published on 04/11/2025 at 18:30, 2 days 19 hours ago Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:00, 2 days 20 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:45, 2 days 20 hours ago NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
Published on 04/11/2025 at 13:49, 3 days ago Statement about the number of shares composing the share capital and the number of voting rights as at March 31, 2025
